1. Dheda K, Barry CE 3rd, Maartens G. Tuberculosis. Lancet 2016; 387:1211–1226.
2. Blomberg B, Fourie B. Fixed-dose combination drugs for tuberculosis: application in standardised treatment regimens. Drugs 2003; 63:535–553.
3. Schaberg T, Rebhan K, Lode H. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J 1996; 9:2026–2030.
4. Bloss E, Kuksa L, Holtz TH, et al. Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000-2004. Int J Tuberc Lung Dis 2010; 14:275–281.
5. Leimane V, Riekstina V, Holtz TH, et al. Clinical outcome of individualized treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet 2005; 365:318–326.
6. Tan WC, Ong CK, Kang SC, Razak MA. Two years review of cutaneous adverse drug reaction from first line antituberculous drugs. Med J Malaysia 2007; 62:143–146.
7. Bigby M. Rates of cutaneous reactions to drugs. Arch Dermatol 2001; 137:765–770.
8. Dodiuk-Gad RP, Chung WH, Valeyrie-Allanore L, Shear NH. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: An Update. Am J Clin Dermatol. 2015;16(6):475-493.
9. Oelze LL, Pillow MT. Phenytoin-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a case report from the emergency department. J Emerg Med. 2013;44(1):75-78.
10. Stern RS, Divito SJ. Stevens-Johnson syndrome and toxic epidermal necrolysis: associations, outcomes, and pathobiology-thirty years of progress but still much to be done. J Invest Dermatol 2017; 137:1004–1008.
11. Kato Y, Sato Y, Nakasu M, Tsuboi R. Immediate type hypersensitivity and late phase reaction occurred consecutively in a patient receiving ethambutol and levofloxacin. Allergy Asthma Clin Immunol 2018; 14:13.
12. Barbaud A, Collet E, Milpied B, et al. A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions. Br J Dermatol 2013; 168: 555–562.
13. Aberer W, Bircher A, Romano A, et al. Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations. Allergy 2003; 58:854–863.
14. Suarez PG, Floyd K, Portocarrero J, et al. Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet 2002; 359:1980–1989.
15. Hildebrand KJ, Atkinson A, Kitai I. Rifampin hypersensitivity in a 2-year-old child with successful rapid oral desensitization. Pediatr Infect Dis J 2014; 33:787.
16. . Logsdon S, Ramirez-Avila L, Castells M, Dioun A. Successful rifampin desensitization in a pediatric patient with latent tuberculosis. Pediatr Allergy Immunol 2014; 25:404–405.
17. Thong BY, Chia FL, Tan SC, et al. A retrospective study on sequential desensitization-rechallenge for antituberculosis drug allergy. Asia Pac Allergy 2014; 4:156–163.